The diagnosis and treatment of pituitary disease in pregnancy represents a special clinical challenge. Not least because there is very little data on the treatment of pregnant patients with pituitary disorders. A selective search of the literature was carried out with the aim of compiling evidence about the diagnosis and treatment of pituitary disease in pregnancy. The search covered the databases PubMed/MEDLINE including PubMed Central and also used the Livivo (ZB MED) search engine. Recent studies were evaluated for recommendations about the care of pregnant patients with hormone-inactive and hormone-active pituitary adenomas (prolactinoma, acromegaly and Cushing's disease), pituitary insufficiency, pituitary apoplexy and hypophysitis. The most well-established forms of treatment are for prolactinoma, due to the incidence of this disease and its impact on fertility. When pregnancy has been confirmed, prolactinoma treatment with dopamine agonists should be paused. Although microprolactinomas rarely increase significantly in size after the administration of dopamine agonists is discontinued, symptomatic tumor growth of macroprolactinomas can occur. In such cases, treatment with dopamine agonists can be resumed. If the primary tumor is large and the risk that it will continue to grow is high, it may be necessary to continue medical treatment from the start of pregnancy. If one of the partners has a pituitary disorder, it is often still possible for many couples to achieve their wish of having children if they receive medical support to plan and the pregnancy is carefully monitored. Given the complexity of pituitary disease, pregnant patients with pituitary disorders should be cared for and treated by a multidisciplinary team in centers specializing in the diagnosis and treatment of pituitary disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461462 | PMC |
http://dx.doi.org/10.1055/a-0794-7587 | DOI Listing |
Psychoneuroendocrinology
December 2024
University of California, Irvine, Department of Psychological Science, Irvine, CA, USA; University of California Los Angeles, Cousins Center for Psychoneuroimmunology, Los Angeles, CA, USA.
Background: Acute psychosocial stress activates the hypothalamic-pituitary-adrenal (HPA) axis and triggers the release of cortisol, a commonly used biomarker of stress reactivity. Yet only 25 % of studies have reported a correlation between cortisol and affective responses to stress. This study aimed to examine whether cortisol reactivity following an acute psychosocial stressor in the laboratory correlated with concurrent positive and negative affect in adolescents, and whether early life adversity (ELA) moderated this relationship.
View Article and Find Full Text PDFCurr Cardiol Rev
January 2025
Division of Applied Biomedical Science and Biotechnology, School of Health Sciences, IMU University, 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia.
Cardiovascular Disease [CVD], the leading cause of death globally, poses a significant burden on the healthcare sector. Its association with stress and Cushing's Syndrome has driven cortisol, the 'stress hormone,' to be a potential candidate in determining CVD risk. Cortisol synthesis and release through the hypothalamic-pituitary-adrenal [HPA] axis are regulated by several hormones and receptors involved in the pathological cascade towards CVD.
View Article and Find Full Text PDFCurr Vasc Pharmacol
January 2025
Department of Cardiology, Ippokrateio University Hospital, Athens, Greece.
Introduction/objective: Emotional, mental, or psychological distress, defined as increased symptoms of depression, anxiety, and/or stress, is common in patients with chronic diseases, such as cardiovascular (CV) disease (CVD).
Methods: Literature was reviewed regarding data from studies and meta-analyses examining the impact of emotional stress on the occurrence and outcome of several CVDs (coronary disease, heart failure, hypertension, arrhythmias, stroke). These influences' pathophysiology and clinical spectrum are detailed, tabulated, and pictorially illustrated.
J Recept Signal Transduct Res
January 2025
Department of Pharmacology, Faculty of Medicine, Ataturk University, Erzurum, Turkey.
Serotonin (5-HT) is a neurotransmitter found throughout the human body that regulates many physiological events arising from the brain and central nervous system (CNS), such as sleep and appetite. However, it has many other functions in systems outside. In addition to the routine expression of 5-HT7 receptors in CNS regions, such as the pituitary gland, spinal cord, and hippocampus, many studies have reported the expression of these receptors in pathological conditions outside.
View Article and Find Full Text PDFThyroid Res
January 2025
Medicine Institute, Geisinger Health System, Wilkes-Barre, PA, USA.
Introduction: Thyroid disease (TD), particularly hypothyroidism, is an important etiology of hyperprolactinemia (HPRL). We conducted a systematic review of the clinical characteristics, management, and outcomes of adults (> 18 years) with this clinical association.
Materials And Methods: We searched PUBMED, SCOPUS, and EMBASE to find eligible articles published in English from any date till 15th December 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!